Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Autor: John A, Dormandy, Bernard, Charbonnel, David J A, Eckland, Erland, Erdmann, Massimo, Massi-Benedetti, Ian K, Moules, Allan M, Skene, Meng H, Tan, Pierre J, Lefèbvre, Gordon D, Murray, Eberhard, Standl, Robert G, Wilcox, Lars, Wilhelmsen, John, Betteridge, Kåre, Birkeland, Alain, Golay, Robert J, Heine, László, Korányi, Markku, Laakso, Marián, Mokán, Antanas, Norkus, Valdis, Pirags, Toomas, Podar, André, Scheen, Werner, Scherbaum, Guntram, Schernthaner, Ole, Schmitz, Jan, Skrha, Ulf, Smith, Jan, Taton, T D M, Williams

Publikováno v: Dormandy, J A, Charbonnel, B, Eckland, D J, Erdmann, E, Massi-Benedetti, M, Moules, I K, Skene, A M, Tan, M H, Lefebvre, P J, Murray, G D, Standl, E & Wilcox, R G 2005, ' Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial ', Lancet, vol. 366, no. 9493, pp. 1279-1289 . https://doi.org/10.1016/S0140-6736(05)67528-9
Dormandy, J A, Charbonnel, B, Eckland, D J, Erdmann, E, Massi-Benedetti, M, Moules, I K, Skene, A M, Tan, M H, Lefebvre, P J, Murray, G D, Standl, E, Wilcox, R G, Wilhelmsen, L, Betteridge, J, Birkeland, K, Golay, A, Heine, R J, Koranyi, L, Laakso, M, Mokan, M, Norkus, A, Pirags, V, Podar, T, Scheen, A, Scherbaum, W, Schernthaner, G, Schmitz, O, Skrha, J, Smith, U & Taton, J 2005, ' Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial ', The Lancet, vol. 366(9493), pp. 1279-1289 .
Lancet, 366(9493), 1279-1289. Elsevier Limited

Patients with type 2 diabetes are at high risk of fatal and non-fatal myocardial infarction and stroke. There is indirect evidence that agonists of peroxisome proliferator-activated receptor gamma (PPAR gamma) could reduce macrovascular complications

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c2b925ba490c64f541b2f444a756d92
https://doi.org/10.1016/s0140-6736(05)67528-9

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

Autor: Erland, Erdmann, John A, Dormandy, Bernard, Charbonnel, Massimo, Massi-Benedetti, Ian K, Moules, Allan M, Skene, T D M, Williams

Publikováno v: Journal of the American College of Cardiology. 49(17)

This analysis from the PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events) study assesses the effects of pioglitazone on mortality and macrovascular morbidity in patients with type 2 diabetes and a previous myocardial infarcti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8a31a555b97a0a28e4bdb94281e07915
https://pubmed.ncbi.nlm.nih.gov/18234918